IPM Product Pipeline

Since our inception in 2002, IPM’s pipeline has included products based on antiretrovirals (ARVs) — the same types of drugs that have proven successful in treating HIV/AIDS and preventing mother-to-child transmission in millions of people around the world.

The pipeline of ARV compounds at IPM is a result of our partnerships with pharmaceutical companies. Through royalty-free licensing agreements for seven ARVs or active pharmaceutical ingredients and exclusive worldwide rights for one ARV called dapivirine, we have access to an array of drugs with a variety of mechanisms of action against HIV infection.

The table below provides information on how IPM compounds work and their stage of development at IPM. Our clinical trials page lists IPM clinical trials that are currently under way.

IPM-licensed ARVs

Compound License Mechanism of action IPM development stage
Dapivirine Janssen Sciences Ireland UC (previously Tibotec) NNRTI: Reverse transcription
  • Clinical: Phase III (dapivirine ring)
  • Phase II- completed    (dapivirine gel)
  • Phase I- ongoing   (dapivirine-darunavir gel)
  • Phase I- completed (dapivirine film)
  • Preclinical (dapivirine-contraceptive ring; dapivirine rectal gel)
DS003 (BMS793) BMS gp120: Cell attachment
  • Preclinical       (DS003 vaginal tablet and vaginal ring)
Maraviroc ViiV Healthcare CCR5: Cell Attachment
  • Clinical: Phase I- ongoing       (maraviroc vaginal and rectal gels)
  • Phase I- completed (maraviroc ring; dapivirine-maraviroc ring)
Tenofovir Gilead NRTI: Reverse transcription 
  • Preclinical*
DS001 (L167), DS004 (L872), DS005 (L882) Merck CCR5: Cell Attachment
  • Early preclinical
DS007 (L-644 peptide) Merck gp41: Cell fusion
  • Early preclinical

* Compound is in different stages of development by other organizations


IPM’s active compounds target different steps in viral replication

The candidate microbicides in IPM’s product pipeline target three different steps in the viral replication cycle: attachment, fusion, and reverse transcription.

  • Cell attachment: Preventing the virus from attaching to human cells
  • Cell fusion: Preventing the virus from entering human cells
  • Reverse transcription: Preventing the virus from reproducing inside human cells  

Learn more about how microbicides work.